News >

Chemoimmunotherapy Combos Solidified as Frontline Standard in Nonsquamous NSCLC

Caroline Seymour
Published: Friday, May 03, 2019

Claude Denham, MD

Claude Denham, MD
The rationale for frontline chemoimmunotherapy in stage IV nonsquamous non–small cell lung cancer (NSCLC), now made evident by several phase III trials, stems from its synergistic activity, stimulatory effects on neoantigens, and tolerable safety profile.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication